Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Pangamic acid and interstate shipment of pangamic acid on the grounds that pangamic acid and pangamic acid products are unsafe for use and have no known nutritional properties. Pangamic acid's distribution in Canada has been prohibited by the then-named Canadian Food and Drug Directorate. Pangamic acid Pangamic acid, also called pangamate, is the name given to the chemical compound described as "-gluconodimethylamino acetic acid", initially promoted by Ernst T. Krebs, Sr. and his son Ernst T. Krebs, Jr. as a medicinal compound for use in treatment of a wide range of diseases. They also termed this chemical "Vitamin B", though it is